Save on Ojjaara with Coupons, Discounts & Savings Programs

Ojjaara is the brand name for momelotinib and is available as an oral tablet.

Ojjaara is available as a 100 mg, 150 mg, 200 mg oral tablet.

• Ojjaara is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia

Ojjaara works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.

• Ojjaara is typically dosed at 200 mg by mouth once daily with or without food.

Ojjaara is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Ojjaara:

• Thrombocytopenia
• Hemorrhage
• Bacterial infection
• Fatigue
• Dizziness
• Diarrhea
• Nausea

Serious side effects are rare with Ojjaara. Contact your healthcare provider immediately if you experience any of the following.

• Infection
• Low platelet and white blood cell counts
• Major cardiovascular events such as heart attack, stroke, and death
• Liver problems
• Blood clots
• Symptoms of new cancer

The following medications may interact with Ojjaara:

• Organic Anion Transporting Polypeptide (OATP)1B1/B3 inhibitors:
• Monitor for adverse reactions.
• Breast Cancer Resistance Protein (BCRP) substrates: Reduce rosuvastatin
• (BCRP substrate) dosage. Follow approved product information
• recommendations for other BCRP substrates.

GlaxoSmithKline

Based on findings from animal studies, Ojjaara may cause fetal harm when administered to a pregnant woman. Ojjaara should only be used during pregnancy if the expected benefits to the mother outweigh the potential risks to the fetus.

• Momelotinib